Hangzhou Tigermed Consulting Co., Ltd.
泰格医药
300347
Shenzhen Stock Exchange
Company Profile
During the reporting period, the company's main business income was 3.6703578 billion yuan, compared with 3.5528401 billion yuan in the same period last year, an increase of 3.31% over the same period last year; the net profit belonging to shareholders of listed companies was 1.388337 billion yuan, compared with 11.920 million yuan in the same period last year, up 16.47% over the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurrent profits and losses was 79,347.44 million yuan, an increase of 2.86% over the same period last year. During the reporting period, the company's main business income was 3.6703578 billion yuan, compared with 3.5528401 billion yuan in the same period last year, an increase of 3.31% over the same period last year, including 2.1033503 billion yuan in clinical trial technical services, compared with the same period last year. 2.1721459 billion yuan, down 3.17% from the same period last year; revenue from clinical trial-related services and laboratory services was 1.5670075 billion yuan, compared with 1.3806942 billion yuan in the same period last year, an increase of 13.49% over the same period last year. (1) Technical services for clinical trials. During the reporting period, the revenue from technical services in clinical trials was 2.1033503 billion yuan, compared with 2.1721459 billion yuan in the same period last year, a decrease of 3.17% over the same period last year, mainly due to the decrease in clinical trials of specific vaccine projects carried out by the company during the reporting period. Excluding these items, the revenue from technical services in clinical trials increased by more than 40% compared with the same period last year. As of June 30, 2023, the company's ongoing drug clinical research projects increased from 607 projects on June 30, 2022 and 680 projects on December 31, 2022 to 772 projects. As of June 30, 2023, the company has 503 drug clinical research projects in China and 269 projects abroad, of which 207 projects are conducting single-region clinical trials abroad (including South Korea, Australia and the United States). There are 62 projects in multi-regional clinical trials. (2) Clinical trial related services and laboratory services. The income of clinical trial-related services and laboratory services was 1.5670075 billion yuan, compared with 1.3806942 billion yuan in the same period last year, an increase of 13.49 percent over the same period last year. During the reporting period, the company's data management and statistical analysis services obtained more new customers at home and abroad, and the number of global customers increased to 296 from 208 in the same period last year. By the end of the reporting period, the company had 859 ongoing projects, of which 553 were implemented by domestic teams and 306 by overseas teams.
Full description
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 3200 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 920 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 130 innovative drugs. For more information about Tigermed, please visit www.tigermed.net Tigermed clinical operation department is composed of numerous highly qualified and experienced CRA & Project manager team, it also has a intact quality assurance and quality control system to ensure all the clinical trial related activities compliance with ICH-GCP and the Chinese GCP. Tigermed supplies full clinical trial service to meet various needs of international and domestic pharmaceutical clients. Tigermed has completed project management system, good relationship with study sites, and widely distributed offices. By delivering faster, more efficient site support and data oversight, Tigermed can make sure trials being executed efficiently and cost effective, as well as enable best management on large scale studies. Tigermed Biometrics division, the second largest division of Tigermed Group, has a large number of highly qualified and dedicated talents. We provide high quality and professional data management and biostatistics services to support clinical development and regulatory submissions. Tigermed Biometrics team operates in Shanghai, Jiaxing, Wuhan, Taiwan and US New Jersey to cover Asia Pacific and North America. We have well-established management and SOP systems. Bioanalytical department has strong technology, regulatory knowledge and rich experiences in the industry, can provide methods to verify compliance with US GLP regulations and sample analysis from the early to late-stage clinical development studies.Team technical staff have extensive experience in GLP laboratory work. Tigermed has professional Site Management Organization (SMO) which provides customized on-site management and clinical operation services for study sites/investigators. Mainly focus on providing real-time assistance to investigators and sites non-medical judgment routine work of clinical trials, so as to ensure the accuracy and integrity of the study data, improve study performances and progress. It is dedicated to pushing forward the standardization and globalization of clinical trials in China. SMO team has set up international standard SOPs . With the background of nursing、medical、pharmacy and other professions, CRCs are not only attuned to ICH-GCP & China GCP and well trained by SOPs and other skills, but also experience with electronic data acquisition system, such as Inform, Data Track, Medidata Rave etc.